{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:37:15Z","timestamp":1792215435513,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interstitial lung disease (ILD) is a life-threatening complication of systemic sclerosis (SSc). Type 2 (Th2) cytokines play a pivotal role in airway disease. Study aim was to evaluate serum level of Th2 interleukin (IL) and chemokine in SSc-ILD. Serum levels of IL-4, IL-5, IL-11, IL-13, IL-21, IL-31 and CXCL-13 were measured by Bio-Plex Multiplex Immunoassays in 60 SSc patients and 20 healthy controls (HC). Pulmonary function tests with diffusion lung capacity for carbon monoxide (DLco) and high resolution computed tomography (HRCT) were performed in SSc patients. ILD is defined as fibrotic changes (ground glass, reticular and honeycombing), assessed by Computer-Aided Lung Informatics for Pathology Evaluation and Ratings (CALIPER) software, affecting at least 10% of the lungs. Serum levels of Th2 cytokines were higher in SSc patients than HC. A linear correlation was observed between ground glass and IL-13 (<jats:italic>r<\/jats:italic>\u2009=\u20090.342, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), IL-21 (<jats:italic>r<\/jats:italic>\u2009=\u20090.345, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), IL-31 (<jats:italic>r<\/jats:italic>\u2009=\u20090.473, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), IL-4 (<jats:italic>r<\/jats:italic>\u2009=\u20090.863, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), IL-5 (<jats:italic>r<\/jats:italic>\u2009=\u20090.249, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and peripheral blood eosinophils (<jats:italic>r<\/jats:italic>\u2009=\u20090.463, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). We found a negative correlation between DLco and IL-4 (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.511, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and peripheral blood eosinophils (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.446, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In the logistic regression analysis, IL-4 is associated with DLco\u2009\u2264\u200960% of the predicted [OR 1.039 (CI 95%: 1.015\u20131.064), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001], whilst\u00a0mRSS [OR 1.138 (CI 95%: 1.023\u20131.266), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05] and IL-4 [OR 1.017 (CI 95%: 1\u20131.034), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05] were associated with ILD. Th2 inflammation could play a key role in early phase of SSc-ILD.<\/jats:p>","DOI":"10.1007\/s10238-023-01125-x","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T05:02:12Z","timestamp":1688187732000},"page":"3517-3525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Type 2 cytokines and scleroderma interstitial lung disease"],"prefix":"10.1007","volume":"23","author":[{"given":"Chiara","family":"Pellicano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Vantaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Colalillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krizia","family":"Pocino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariapaola","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-8093","authenticated-orcid":false,"given":"Edoardo","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9.","journal-title":"Lancet"},{"key":"1125_CR2","doi-asserted-by":"publisher","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, et al. EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80:219\u201327. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217455.","DOI":"10.1136\/annrheumdis-2020-217455"},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809\u201315. https:\/\/doi.org\/10.1136\/ard.2009.114264.","journal-title":"Ann Rheum Dis"},{"key":"1125_CR4","doi-asserted-by":"publisher","unstructured":"Kase K, Watanabe S, Saeki S, et al. Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease. J Thorac Dis 2021;13:4146\u201355. https:\/\/doi.org\/10.21037\/jtd-20-2596.","DOI":"10.21037\/jtd-20-2596"},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","volume":"55","author":"O Distler","year":"2020","unstructured":"Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55:1902026. https:\/\/doi.org\/10.1183\/13993003.02026-2019.","journal-title":"Eur Respir J"},{"key":"1125_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8:304\u201320. https:\/\/doi.org\/10.1016\/S2213-2600(19)30480-1.","journal-title":"Lancet Respir Med"},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1513\/AnnalsATS.201606-426FR","volume":"13","author":"ER Volkmann","year":"2016","unstructured":"Volkmann ER, Tashkin DP. Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann Am Thorac Soc. 2016;13:2045\u201356. https:\/\/doi.org\/10.1513\/AnnalsATS.201606-426FR.","journal-title":"Ann Am Thorac Soc"},{"key":"1125_CR8","doi-asserted-by":"publisher","unstructured":"Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 58:1165\u201374. https:\/\/doi.org\/10.1002\/art.23406.","DOI":"10.1002\/art.23406"},{"key":"1125_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199\u2013210. https:\/\/doi.org\/10.1002\/path.2277.","journal-title":"J Pathol"},{"key":"1125_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00403-019-01972-3","volume":"312","author":"JK Nguyen","year":"2020","unstructured":"Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4\/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312:81\u201392. https:\/\/doi.org\/10.1007\/s00403-019-01972-3.","journal-title":"Arch Dermatol Res"},{"key":"1125_CR11","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24:328\u201332.","journal-title":"J Rheumatol"},{"key":"1125_CR12","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1021\/acs.jproteome.6b00367","volume":"16","author":"KV Soman","year":"2017","unstructured":"Soman KV, Stafford SJ, Pazdrak K, et al. Activation of human peripheral blood eosinophils by cytokines in a comparative time-course proteomic\/phosphoproteomic study. J Proteome Res. 2017;16:2663\u201379. https:\/\/doi.org\/10.1021\/acs.jproteome.6b00367.","journal-title":"J Proteome Res"},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3831","volume":"15","author":"TA Wynn","year":"2015","unstructured":"Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15:271\u201382. https:\/\/doi.org\/10.1038\/nri3831.","journal-title":"Nat Rev Immunol"},{"key":"1125_CR14","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.acra.2017.07.002","volume":"24","author":"C Kloth","year":"2017","unstructured":"Kloth C, Blum AC, Thaiss WM, et al. Differences in texture analysis parameters between active alveolitis and lung fibrosis in chest CT of patients with systemic sclerosis: a feasibility study. Acad Radiol. 2017;24:1596\u2013603. https:\/\/doi.org\/10.1016\/j.acra.2017.07.002.","journal-title":"Acad Radiol"},{"key":"1125_CR15","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347. https:\/\/doi.org\/10.1002\/art.38098.","journal-title":"Arthritis Rheum"},{"key":"1125_CR16","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202\u20135.","journal-title":"J Rheumatol"},{"key":"1125_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini G, Iudici M, Walker UA, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76:270\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209768.","journal-title":"Ann Rheum Dis"},{"key":"1125_CR18","first-page":"2159","volume":"26","author":"TA Medsger Jr","year":"1999","unstructured":"Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26:2159\u201367.","journal-title":"J Rheumatol"},{"key":"1125_CR19","first-page":"663","volume":"25","author":"M Cutolo","year":"2007","unstructured":"Cutolo M, Matucci CM. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007;25:663\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, et al. ATS\/ERS Task Force. Standardisation of spirometry Eur Respir J. 2005;26:319\u201338. https:\/\/doi.org\/10.1183\/09031936.05.00034805.","journal-title":"Standardisation of spirometry Eur Respir J"},{"key":"1125_CR21","doi-asserted-by":"publisher","unstructured":"Distler O, Highland KB, Gahlemann M, et al; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380:2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1903076.","DOI":"10.1056\/NEJMoa1903076"},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s10067-020-04938-3","volume":"39","author":"AM Ferrazza","year":"2020","unstructured":"Ferrazza AM, Gigante A, Gasperini ML, et al. Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER. Clin Rheumatol. 2020;39:1537\u201342. https:\/\/doi.org\/10.1007\/s10067-020-04938-3.","journal-title":"Clin Rheumatol"},{"key":"1125_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/BOR.0b013e32832fd69e","volume":"21","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol. 2009;21:617\u201322. https:\/\/doi.org\/10.1097\/BOR.0b013e32832fd69e.","journal-title":"Curr Opin Rheumatol"},{"key":"1125_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O'Reilly","year":"2012","unstructured":"O\u2019Reilly S, H\u00fcgle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012;51:1540\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kes090.","journal-title":"Rheumatology (Oxford)"},{"key":"1125_CR25","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","volume":"12","author":"A Kuzumi","year":"2021","unstructured":"Kuzumi A, Yoshizaki A, Matsuda KM, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12:5947. https:\/\/doi.org\/10.1038\/s41467-021-26099-w.","journal-title":"Nat Commun"},{"key":"1125_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08916934.2017.1416467","volume":"51","author":"RSG Gon\u00e7alves","year":"2018","unstructured":"Gon\u00e7alves RSG, Pereira MC, Dantas AT, et al. IL-17 and related cytokines involved in systemic sclerosis: Perspectives. Autoimmunity. 2018;51:1\u20139. https:\/\/doi.org\/10.1080\/08916934.2017.1416467.","journal-title":"Autoimmunity"},{"key":"1125_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/art.1780340406","volume":"34","author":"R Gustafsson","year":"1991","unstructured":"Gustafsson R, Fredens K, Nettelbladt O, H\u00e4llgren R. Eosinophil activation in systemic sclerosis. Arthritis Rheum. 1991;34:414\u201322. https:\/\/doi.org\/10.1002\/art.1780340406.","journal-title":"Arthritis Rheum"},{"key":"1125_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","volume":"201","author":"D Khanna","year":"2020","unstructured":"Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201:650\u201360. https:\/\/doi.org\/10.1164\/rccm.201903-0563CI.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR29","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1186\/s40064-016-3106-4","volume":"5","author":"K Ando","year":"2016","unstructured":"Ando K, Nakashita T, Kaneko N, Takahashi K, Motojima S. Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity. Springerplus. 2016;5:1401. https:\/\/doi.org\/10.1186\/s40064-016-3106-4.","journal-title":"Springerplus"},{"key":"1125_CR30","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.2106012","volume":"165","author":"D Bouros","year":"2002","unstructured":"Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581\u20136. https:\/\/doi.org\/10.1164\/rccm.2106012.","journal-title":"Am J Respir Crit Care Med"},{"key":"1125_CR31","doi-asserted-by":"publisher","unstructured":"Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1190;88:470\u20136. https:\/\/doi.org\/10.1016\/0002-9343(90)90425-d.","DOI":"10.1016\/0002-9343(90)90425-d"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01125-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01125-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01125-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:23:38Z","timestamp":1698783818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01125-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01125-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Sapienza University (IRB 0304).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}